Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
Hemasphere
|
June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
Chiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009
Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Haematologica
|
May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
Sabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
British Journal of Haematology
|
July 24, 2012
Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups
Andishe Attarbaschi, Maria Morak, Gunnar Cario, et al.
British Journal of Haematology
|
August 16, 2002
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group
Anna Maria Testi, Ilaria Del Giudice, William Arcese, et al.
Blood
|
July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Haematologica
|
October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
JCO Global Oncology
|
March 7, 2025
Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
Priya Kumar, Monika L Metzger, John K Choi, et al.
Blood
|
January 14, 2014
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
Valentino Conter, Maria Grazia Valsecchi, Rosanna Parasole, et al.
Ebiomedicine
|
August 19, 2022
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
Grazia Fazio, Silvia Bresolin, Daniela Silvestri, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
Hemasphere
|
June 12, 2023
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
Chiara Palmi, Silvia Bresolin, Stefanie Junk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2025
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009
Hanna Gottschalk, Anja Möricke, Valentino Conter, et al.
Haematologica
|
May 30, 2013
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
Sabina Chiaretti, Antonella Vitale, Gianni Cazzaniga, et al.
British Journal of Haematology
|
July 24, 2012
Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups
Andishe Attarbaschi, Maria Morak, Gunnar Cario, et al.
British Journal of Haematology
|
August 16, 2002
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group
Anna Maria Testi, Ilaria Del Giudice, William Arcese, et al.
Blood
|
July 2, 2011
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
Martin Schrappe, Maria Grazia Valsecchi, Claus R Bartram, et al.
Haematologica
|
October 29, 2017
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, et al.
JCO Global Oncology
|
March 7, 2025
Prospective Evaluation of the Pathologic Diagnosis and Treatment Outcomes of Pediatric Burkitt Lymphoma in the Central American Pediatric Hematology-Oncology Association Consortium
Priya Kumar, Monika L Metzger, John K Choi, et al.
Blood
|
January 14, 2014
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
Valentino Conter, Maria Grazia Valsecchi, Rosanna Parasole, et al.
Ebiomedicine
|
August 19, 2022
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120
Grazia Fazio, Silvia Bresolin, Daniela Silvestri, et al.
Page
of 11